Rohann Correa reviews the indications and outcomes of SBRT in T1 tumors, highlighting the evolving perspectives on radiation therapy and its results. We are all excited to see more in the near future SIU-Urology #SIU2024NewDelhi

#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. Giulia Marvaso shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients by Natalia Jiménez et al buff.ly/3TTC2Z7 #UroSoMe #MedTwitter #EUO #PCa #ProstateCancer

📝 Curs Multidisciplinari per Residents i Adjunts en Càncer Urotelial. 📅 Dijous 14 de Novembre de 2024. 🏨 Hotel Seventy Barcelona. c/ Còrsega 344. Oscar Buisan Teresa Bonfill Fernando Lozano Joel Mases A. Rodríguez-Vida, S. Cros, L. Izquierdo & P. Servian.

Another setting where SBRT underutilized IMO in HCC is bridge to transplant. I am convinced w modern tech, SBRT can safely prevent local progression in most. Study shows similar transplant outcomes post SBRT/TACE/RFA, despite SBRT pts w worse liver fxn journal-of-hepatology.eu/article/S0168-…

El càncer de bufeta te pitjor pronòstic en dones. Aplicar #perspectivagenere en medicina es fonamental per individualitzar estratègies. Orgulloses de presentar en la “ I Jornada #salutsexegenere els resultats preliminars del que serà una tesi doctoral. Recerca fonamental.

"Oligo"-no more! 🇨🇦ARREST phase I out now IJROBP - The Red Journal - Sue Yom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏

Just released ! Happy to share peace 1 metastatic hormones sensitive prostate cancer radiotherapy Lancet article. GETUG authors.elsevier.com/c/1k8U7V-4XOuxY

🎉 Avui fem història al Hospital Clínic !! Hem realitzat el *PRIMER* tractament amb radiocirurgia al nostre hospital. Una nova tecnologia que ens permet cuidar millor dels nostres pacients. Gràcies a totes les persones que ho han fet possible! 💪 #OncRadClinic

Us presiento el mapa lengüistico de la España peninsular y Baliares

Merci beaucoup au congrès GOCO et à l'OncoPole de Touluse de m'avoir invité à participer au congrès ☢️🇫🇷 Je suis ravi de parler d'écologie en oncologie radiothérapeutique et de profiter de cette ville et de ces collègues 🌱

Se "cuela" un estudio andaluz 💚 en el Congreso del Grup Oncològic Català-Occità (GOCO) en Toulouse 🇫🇷 Enhorabuena 👏 Dr Elías Gomis👨‍⚕️🩺! #ConMuchoAcento

Thank you to everyone who participated in #BCLCUpdate2024 Your dedication made this event a success. Together, we continue advancing knowledge and care in liver cancer. @BCLCGroup Hospital Clínic @CIBERehd JordiRimola Maxime Ronot @Caldera60373705 Alexandre Soler Perromat Marta Fortuny

🎓📚 Nuestro agradecimiento 🤗 a la Universidad de Sevilla Universidad de Sevilla 🏫 por la difusión de los resultados de la tesis doctoral con mención internacional y calificada cum laude 🏅✨de nuestro compañero Dr Elías Gomis🌍🎖️ 👩‍⚕️🔬 Másℹ️👇 us.es/actualidad-de-…

I was honoured to give a talk on 20 years of the STAMPEDE trial at PCF Science Retreat. Link below to the video of the talk The ICR MRC Clinical Trials Unit at UCL AttardLab

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

Safe practice of spine SBRT requires high-quality data about SC dose tolerance - Cohort study 2051 pts - 30 cases of RM, 19 of which G3 to G4 - 2a rate of G1-4 RM 1.8% - cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years jamanetwork.com/journals/jamao…

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:

El coste de una consulta en Atención Primaria son 60€. El de una consulta hospitalaria 121€. El de una urgencia no ingresada 339€. No cuidar la Atención Primaria es una mala decisión. A todos los niveles.

Bon any a tothom!! Després del 2024, on el metro de Barcelona va fer 100 anys, ja en 2025 ens fem la pregunta de... com serà la xarxa de metro d'aquí a uns anys?🤔 Comencem fil🧵